Rthritis and Post-Treatment Persistence in Micesuggests that at least a part of dbpAB infected mice that are treated with antibiotics at two weeks of infection ZM241385 msds harbour B. burgdorferi in the joints at that time point, and thus the lack of persisting DNA at 15 weeks of infection in the joints of these animals (Table 3, groups 10 and 12) cannot be explained by the absence of B. burgdorferi from the joints already before the treatment.Effect of ceftriaxone and anti-TNF-alpha treatments on antibody responsesCeftriaxone treatment, or ceftriaxone followed by anti-TNF-alpha treatment, did not abrogate the development of IgG antibodies EPZ-5676 msds against the whole cell antigen in dbpAB/dbpAB infected mice (Fig. 3A, groups 7, 9 and 11). Indeed, there was a similar and statistically significant increase in the antibody levels from two to 15 weeks both in the untreated and treated mice (P < 0.001, Fig. 3C). In contrast, the antibody levels in the sera of dbpAB infected and treated mice were lower than in the sera of untreated dbpAB infected mice (Fig. 3A, groups 8, 10 and 12). Also, there was no statistically significant increase in the antibodies of dbpAB infected and treated mice from two to 15 weeks, while the increase was significant in the untreated animals (P = 0.027, Fig. 3D). C6 antibodies, and also anti-DbpA and anti-DbpB antibodies, in dbpAB/dbpAB infected mice were statistically significantly lower in the treatment groups than in the untreated group (S1A, B and C Fig., groups 7, 9 and 11). No significant increase was detected in C6 antibodies of dbpAB infected untreated mice when compared to the antibody levels of dbpAB infected and treated animals (S1A Fig., groups 8, 10 and 12). As expected, no anti-DbpA and antiDbpB antibodies were detected in the samples of dbpAB infected mice (S1B and C Fig., groups 8, 10 and 12). In conclusion, the finding that antibodies against whole cell antigen in the sera of dbpAB/ dbpAB infected and treated mice are similarly increased 12 weeks after the treatment as the antibodies in the sera of dbpAB/dbpAB infected and untreated mice suggests the persistence of antigenic borrelial remnants in the antibiotic treated animals.Persistence of B. burgdorferi DNA in mouse joints after ceftriaxone treatment at six weeksExperiment IV was performed to study the role DbpA and B in the persistence of borrelial DNA in mice treated with antibiotics at six weeks of the infection. This treatment time point was selected because at that point, also dbpAB bacteria have disseminated and infected mice are spirochetemic as indicated by the ear biopsy sample cultures at six weeks of infection (Table 2, group 8), and by the culture results of Experiment I (Table 1). In this set up at 15 weeks of infection, a similar finding was evident as in Experiment II. All tested tissue samples of dbpAB/dbpAB and dbpAB infected and untreated mice were culture and PCR positive (Table 5, groups 17 and 18), while after ceftriaxone treatment, all samples of were culture negative (Table 5, groups 19 and 20). Importantly, all joint samples of dbpAB/dbpAB infected and ceftriaxone treated animals retained borrelial DNA while none of the ear and bladder samples did (Table 5, group 19). The qPCR results of the joint samples revealed that there was no significant difference in the DNA load between the untreated and treated dbpAB/dbpAB infected mice (Fig. 4, groups 17 and 19). Ceftriaxone treatment at six weeks time point abolished the joint swelling of dbpAB/dbpAB.Rthritis and Post-Treatment Persistence in Micesuggests that at least a part of dbpAB infected mice that are treated with antibiotics at two weeks of infection harbour B. burgdorferi in the joints at that time point, and thus the lack of persisting DNA at 15 weeks of infection in the joints of these animals (Table 3, groups 10 and 12) cannot be explained by the absence of B. burgdorferi from the joints already before the treatment.Effect of ceftriaxone and anti-TNF-alpha treatments on antibody responsesCeftriaxone treatment, or ceftriaxone followed by anti-TNF-alpha treatment, did not abrogate the development of IgG antibodies against the whole cell antigen in dbpAB/dbpAB infected mice (Fig. 3A, groups 7, 9 and 11). Indeed, there was a similar and statistically significant increase in the antibody levels from two to 15 weeks both in the untreated and treated mice (P < 0.001, Fig. 3C). In contrast, the antibody levels in the sera of dbpAB infected and treated mice were lower than in the sera of untreated dbpAB infected mice (Fig. 3A, groups 8, 10 and 12). Also, there was no statistically significant increase in the antibodies of dbpAB infected and treated mice from two to 15 weeks, while the increase was significant in the untreated animals (P = 0.027, Fig. 3D). C6 antibodies, and also anti-DbpA and anti-DbpB antibodies, in dbpAB/dbpAB infected mice were statistically significantly lower in the treatment groups than in the untreated group (S1A, B and C Fig., groups 7, 9 and 11). No significant increase was detected in C6 antibodies of dbpAB infected untreated mice when compared to the antibody levels of dbpAB infected and treated animals (S1A Fig., groups 8, 10 and 12). As expected, no anti-DbpA and antiDbpB antibodies were detected in the samples of dbpAB infected mice (S1B and C Fig., groups 8, 10 and 12). In conclusion, the finding that antibodies against whole cell antigen in the sera of dbpAB/ dbpAB infected and treated mice are similarly increased 12 weeks after the treatment as the antibodies in the sera of dbpAB/dbpAB infected and untreated mice suggests the persistence of antigenic borrelial remnants in the antibiotic treated animals.Persistence of B. burgdorferi DNA in mouse joints after ceftriaxone treatment at six weeksExperiment IV was performed to study the role DbpA and B in the persistence of borrelial DNA in mice treated with antibiotics at six weeks of the infection. This treatment time point was selected because at that point, also dbpAB bacteria have disseminated and infected mice are spirochetemic as indicated by the ear biopsy sample cultures at six weeks of infection (Table 2, group 8), and by the culture results of Experiment I (Table 1). In this set up at 15 weeks of infection, a similar finding was evident as in Experiment II. All tested tissue samples of dbpAB/dbpAB and dbpAB infected and untreated mice were culture and PCR positive (Table 5, groups 17 and 18), while after ceftriaxone treatment, all samples of were culture negative (Table 5, groups 19 and 20). Importantly, all joint samples of dbpAB/dbpAB infected and ceftriaxone treated animals retained borrelial DNA while none of the ear and bladder samples did (Table 5, group 19). The qPCR results of the joint samples revealed that there was no significant difference in the DNA load between the untreated and treated dbpAB/dbpAB infected mice (Fig. 4, groups 17 and 19). Ceftriaxone treatment at six weeks time point abolished the joint swelling of dbpAB/dbpAB.